A national spinal muscular atrophy registry for real world evidence

One of NMD4C’s many important initiatives is the development of neuromuscular disease (NMD) patient registries. Patient registries collect information about individuals who are affected by a particular condition and are a particularly important research and networking tool for rare diseases. The data collected may be used for a range of purposes, from research into specific features of the disease to clinical trial feasibility planning and recruitment. Patients who join registries can be contacted with information relevant to their condition and notified when they may be eligible for research studies and clinical trials.

NMD4C works closely with the Canadian Neuromuscular Disease Registry (CNDR), a Canada-wide registry of people diagnosed with an NMD. It collects important medical information from patients across the country to improve the understanding of NMD and accelerate the development of new therapies. Over 4500 NMD patients have registered from across Canada since the CNDR’s launch in 2010. With their data, the CNDR has facilitated 35 trials and 75 data inquiries and research projects.

Recently, the CNDR undertook an iterative multi-stakeholder process to expand its spinal muscular atrophy (SMA) dataset to capture items relevant to patient outcomes in the use of the new therapies such as nusinursen (Spinraza). This will serve as a longitudinal, prospective, multi-centre, observational study of patients with SMA in Canada designed to evaluate the safety and effectiveness of novel therapies and provide practical information unattainable in trials. In the development of this new dataset, the team also aimed to standardize outcome measures across the network and the broader Canadian community, and to align its measures with global datasets to facilitate collaboration. The data collected with this expanded dataset will be essential to inform improvements in care and access to therapy for all SMA patients.

Click here to read more about this project

Many NMD4C investigators and members were on the team involved in expanding the CNDR’s SMA dataset:

NMD4C steering committee involved in the project:

NMD4C investigators involved in the project:

NMD4C collaborators involved in the project:

NMD4C members involved in the project:

  • Nicolas Chrestian
  • Susan Dojeiji
  • Nicolas Dupré
  • Hernan Gonorazky
  • Aaron Izenberg
  • Alier Marerro
  • Anna McCormick
  • Gerald Pfeffer
  • Stephanie Plamondon
  • Xavier Rodrigue
  • Jordan Sheriko
Annotation 2020-07-03 092543

Read next...

2024 NMD4C Annual Meeting

NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the Annual NMD4C Meeting on September 27th in Calgary! Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date.

LEARNMD logo

NMD4C Launch Educational Platform LEARNMD

LEARNMD is an online educational platform offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide.

CNDR logo4x3

October 2024 Updates from the Canadian Neuromuscular Disease Registry

The Canadian Neuromuscular Disease Registry (CNDR) is pleased to share updates on several exciting initiatives this fall!

2025 early career awards

2025 Annual NMD4C Early-Career Awards Open for Applications

We are excited to announce the opening of our third annual early-career awards competition!

Canadian neuromuscular fellows attend the WCNMC in Calgary, AB.

NMD4C Provides Opportunity for Neuromuscular Fellows to Build Clinical Network at National Meeting

We are pleased to share that this fall we provided an opportunity for clinical neuromuscular fellows to attend NMD4C’s annual meeting and the Western Canadian Neuromuscular Conference (WCNMC) in Calgary.

newborn screening

NMD4C Investigators Submit Response to CDA Draft Guidance on NBS

A group of NMD4C investigators recently submitted a response to the discussion paper from Canada’s Drug Agency outlining its approach for developing Canadian newborn screening guidance.